Related references
Note: Only part of the references are listed.The economic impact of compassionate use of medicines
Claudio Jommi et al.
BMC HEALTH SERVICES RESEARCH (2021)
National Early Access Programs and Clinical Trials: What Opportunities for Early Access to Therapeutic Innovations for Patients With Malignant Melanoma?
Emmanuelle Kempf et al.
CANCER (2021)
Early Access in Oncology: Why Is It Needed?
Giovanni Apolone et al.
GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT (2019)
Early market access of cancer drugs in the EU
J. Martinalbo et al.
ANNALS OF ONCOLOGY (2016)
Expanded Access Programme: looking for a common definition
Antonella Iudicello et al.
TRIALS (2016)
EARLY ACCESS PROGRAMMES (EAPS): REVIEW OF THE EUROPEAN SYSTEM
D. Urbinati et al.
VALUE IN HEALTH (2012)
The European Medicines Agency: An Overview of Its Mission, Responsibilities, and Recent Initiatives in Cancer Drug Regulation
Francesco Pignatti et al.
CLINICAL CANCER RESEARCH (2011)
Bridging the efficacy-effectiveness gap: a regulator's perspective on addressing variability of drug response
Hans-Georg Eichler et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Share Paper
